文献速递妇科

评估新实施的基于MRI的宫颈癌近距离放疗项目的结局与毒性

Evaluating outcomes and toxicities for a newly implemented MRI-based brachytherapy program for cervical cancer.
PubMed 文献 · Gynecol Oncol · 2024-03-15

该研究回顾性分析了美国学术中心98例接受基于MRI的近距离放疗的局部晚期宫颈癌患者,中位随访24.5个月。3年局部控制率、无进展生存率和总生存率分别为84%、61.7%和76.1%,慢性3级及以上膀胱、直肠乙状结肠和阴道毒性分别为8.2%、4.1%和1.0%。

要点

  • 基于MRI的近距离放疗3年局部控制率为84%。
  • 慢性3级及以上膀胱、直肠乙状结肠和阴道毒性分别为8.2%、4.1%和1.0%。
  • 3年无进展生存率和总生存率分别为61.7%和76.1%。

核心结论

  • 基于MRI的近距离放疗显示出优异的局部控制和可接受的高级别并发症发生率。
  • 这些结果在肿瘤体积相对较大且局部病变广泛的人群中可以实现。

研究设计与样本

  • 回顾性综述,纳入98例接受基于MRI的近距离放疗的宫颈癌患者。
  • 外照射放疗标准为45 Gy分25次,每周顺铂化疗。
  • MRI在近距离放疗施源器原位时进行。
  • 剂量规格最常为7 Gy分4次,优化目标为D90 HR-CTV EQD2 85-95 Gyα/β=10 Gy,分2次植入,每次2分次。

主要发现

  • 中位随访24.5个月(IQR 11.9-39.8)。
  • IIIA-IVB期占31.6%。
  • 剂量学结果包括中位GTV D98为101.0 Gy(IQR 93.3-118.8),HR-CTV D90为89 Gy(IQR 86.1-90.6)。
  • 中位D2cc膀胱、直肠、乙状结肠和肠道剂量分别为82.1 Gy(IQR 75.9-88.0)、65.9 Gy(IQR 59.6-71.2)、65.1 Gy(IQR 57.7-69.6)和55 Gy(IQR 48.9-60.9)。
  • 慢性3级及以上毒性见于膀胱(8.2%)、直肠乙状结肠(4.1%)和阴道(1.0%)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: We report an updated analysis of the outcomes and toxicities of MRI-based brachytherapy for locally advanced cervical cancer from a U.S. academic center. METHODS: A retrospective review was performed on patients treated with MRI-based brachytherapy for cervical cancer. EBRT was standardly 45 Gy in 25 fractions with weekly cisplatin. MRI was performed with the brachytherapy applicator in situ. Dose specification was most commonly 7 Gy for 4 fractions with optimization aim of D90 HR-CTV EQD2 of 85-95 Gyα/β=10 Gy in 2 implants each delivering 2 fractions. RESULTS: Ninety-eight patients were included with median follow up of 24.5 months (IQR 11.9-39.8). Stage IIIA-IVB accounted for 31.6% of cases. Dosimetry results include median GTV D98 of 101.0 Gy (IQR 93.3-118.8) and HR-CTV D90 of 89 Gy (IQR 86.1-90.6). Median D2cc bladder, rectum, sigmoid, and bowel doses were 82.1 Gy (IQR 75.9-88.0), 65.9 Gy (IQR 59.6-71.2), 65.1 Gy (IQR 57.7-69.6), and 55 Gy (IQR 48.9-60.9). Chronic grade 3+ toxicities were seen in the bladder (8.2%), rectosigmoid (4.1%), and vagina (1.0%). Three-year LC, PFS, and OS were estimated to be 84%, 61.7%, and 76.1%, respectively. CONCLUSION: MRI-based brachytherapy demonstrates excellent local control and acceptable rates of high-grade morbidity. These results are possible in our population with relatively large volume primary tumors and extensive local disease.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Ross DH, Gomez K, Harmon G, et al. Evaluating outcomes and toxicities for a newly implemented MRI-based brachytherapy program for cervical cancer. Gynecol Oncol. 2024. PMID: 38492475. doi:10.1016/j.ygyno.2024.03.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。